Icagen has entered into a collaboration and licensing agreement with Pfizer for potential treatments for pain and related disorders and announced an equity investment of up to $15 million by Pfizer.
The companies will develop and commercialize compounds that target three specific sodium ion channels, which are important in the generation of electrical signals in nerve fibers that mediate the initiation, transmission and sensation of pain, Icagen said.
More
No comments:
Post a Comment